• About us
• Contact

Advertisement

Organisation › Details

Genentech Inc.

Founded 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products and licenses several additional products to other companies. The company has headquarters in South San Francisco, California and is listed on the New York Stock Exchange under the symbol DNA. *

 

	Start	1990-01-01 existent
	Group	Roche (Group)
	Industry	BIOTECH
	Region	South San Francisco, CA
	Country	United States (USA)
	Street	One DNA Way
	City	94080-4990 South San Francisco, CA
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
	Currency	USD
	Annual sales	9,284,000,000 (revenues, total operating, consolidated (2006) 2006-12-31)
	Profit	2,113,000,000 (2006-12-31)
	Cash	2,493,000,000 (2006-12-31)
		* Document for »About Section«:
		Record changed: 2026-05-02

Advertisement

More documents for Roche (Group)

• [1] OMass Therapeutics Ltd.. (9/2/25). "Press Release: OMass Therapeutics Enters into Exclusive Collaboration and License Agreement with Genentech to Develop and Commercialize Therapies for Inflammatory Bowel Disease". Oxford....
• [2] Oxford BioTherapeutics Ltd.. (3/19/25). "Press Release: Oxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer". Oxford & San Jose, CA....
• [3] Immunic, Inc.. (7/24/24). "Press Release: Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec". New York, NY....
• [4] Pfizer Inc.. (4/26/24). "Press Release: U.S. FDA Approves Pfizer’s Beqvez (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B". New York, NY....
• [5] PhoreMost Ltd.. (9/6/22). "Press Release: PhoreMost Enters Multi-project Drug Target Discovery Collaboration with Roche". Cambridge....
• [6] Forbion Capital Partners. (7/20/22). "Press Release: Forbion Appoints Dr. Peter Høngaard Andersen as Operating Partner and Dr. Matt Cooper as Venture Partner". Naarden....
• [7] Bicycle Therapeutics plc. (7/12/22). "Press Release: Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration". Cambridge & Boston, MA....
• [8] Bicycle Therapeutics plc. (21/10/26). "Press Release: Bicycle Therapeutics Announces Expansion of Genentech Immuno-Oncology Collaboration". Cambridge & Boston, MA....
• [9] Roche. (10/18/21). "Press Release: Roche Announces Collaboration with Ibex Medical Analytics to Develop Artificial Intelligence-based Digital Pathology Applications for Improved Patient Care". Santa Clara, CA....
• [10] Atbtherapeutics. (10/20/20). "Press Release: Atbtherapeutics Strengthens Its Scientific Advisory Board to Support the Development of its Novel Platform and Portfolio". Belgium....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2026. Made in Germany.